Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans.
Human parotid saliva histidine-rich polypeptides exerted antifungal activity against Candida albicans at concentrations similar to the known antifungal activity of the imidazole antibiotics. Inhibition of both growth and viability could be demonstrated by optical density monitoring and plating assays. Inhibition of growth was observed to be greatest when the histidine-rich polypeptides were added to the inoculum before addition to the growth media. However, complete inhibition by these polypeptides was still noted during active growth at turbidities of C. albicans corresponding to 10(6) CFU/ml. At higher cell densities, growth was delayed but not halted under the experimental conditions investigated. Candidacidal activity was observed with both growing and nongrowing cells. With respect to the latter, reaction of cells in buffer with the histidine-rich polypeptides for a period of 30 min resulted in killing of greater than 90% of two different strains of C. albicans, whereas a third strain was found to be less susceptible. Moreover, the kinetics of loss of cell viability correlated with the loss of potassium from the cells. In addition to the histidine-rich polypeptides, hen egg white lysozyme, poly-L-lysine, and poly-L-histidine affected C. albicans. Both of the polyamino acids completely inhibited the growth of the yeast whereas lysozyme was not as potent. Where delays in growth were observed for all of these agents, including the histidine-rich polypeptides, turbidities reached those of untreated controls after a 24-h period. Enhanced effects were noted if C. albicans was preincubated with these agents in 0.025 2-(N-morpholino)-ethanesulfonic acid buffer, pH 5.2, before growth in the yeast synthetic medium.
D002176:Candida albicans / Q000187:drug effects* / Q000254:growth & development; D006639:Histidine; D006801:Humans; D009113:Muramidase / Q000378:metabolism; D010306:Parotid Gland / Q000378:metabolism*; D010455:Peptides / Q000494:pharmacology; D011107:Polylysine / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D011506:Proteins / Q000494:pharmacology*; D012463:Saliva / Q000032:analysis*; D000099053:Histidine-Rich Glycoprotein
D010455:Peptides; D011506:Proteins; D000099053:Histidine-Rich Glycoprotein; D011107:Polylysine; C033223:polyhistidine; D006639:Histidine; D009113:Muramidase; D011188:Potassium